STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study
Novo Nordisk’s next-generation weight loss drug CagriSema, one of the company’s key hopes to help it regain its footing in the increasingly competitive obesity market, failed in a key study that compared it to rival Eli Lilly’s tirzepatide, Novo said Monday. The open-l...
🔗 Read more: https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/?utm_campaign=rss
#News #Business #Health #Finance #Biology #Medicine #Science
Edited
www.statnews.com
STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study
Novo Nordisk’s next-generation weight loss drug CagriSema, one of the company’s key hopes to help it regain its footing in the increasingly competitive obesity market, failed in a key study that compared it to rival Eli Lilly’s tirzepatide, Novo said Monday. The open-label REDEFINE 4 study was...
Comments
Log in to leave a comment.
No comments yet. Be the first to comment!